Product Images Rivastigmine Tartrate

Each capsule contains rivastigmine base, a medication used to treat dementia. It is manufactured by Alembic Pharmaceuticals Limited and distributed by Breckenridge Pharmaceutical, Inc. It is available in a tightly sealed container and must be stored at controlled room temperature. Further dosage information can be found in the insert provided. NDC code 51991-793-06. Keep out of reach of children.*

This is a medication in the form of hard gelatin capsules that contain Rivastigmine Tartrate USP, equivalent to 3 mg of Rivastigmine base. It should be stored at 25°C (77°F), and dispensed in a tight container. The manufacturer is Alembic Pharmaceuticals Limited, and this medication should be kept out of the reach of children. No other information is available due to the formatting and readability of the text.*

Each capsule contains rivastigmine, a medication used to treat dementia in people with Alzheimer's disease or Parkinson's disease. The capsules should be stored at room temperature and kept out of reach of children. The medication is distributed by Breckenridge Pharmaceutical and manufactured by Alembic Pharmaceuticals in India. The capsule's dosing information should be found in the package insert. The product is available in a container of 60 capsules, and the NDC number is 51991-795-06.*

This appears to be a chart or graph with headings for "Clinical Improvement" and "Clinical Decline" with data points labeled as "Mean (+/- SEM) Change from Baseline" and "AADAS-cog Rating". The chart also has a time axis labeled in weeks. However, without more context or clearer text, it is difficult to provide a more specific description.*

The text describes a chart showing the Cumulative Percentage of Patients with no change and changes in the ADAS-cog score for different treatments. The treatments included TeamentGrop, Placebo, and t-4mgly 69, and 612mgidy. However, there is no further information available to explain the meaning of these treatments or ADAS-cog scores.*

This appears to be a table showing the percentage of patients with different levels of improvement based on CIBIC-Plus rating. The table compares the results of a placebo group and groups taking doses of 4mg and 6-12mg of an unknown medication. However, without more context it is difficult to determine the specifics of what is being measured and how the results should be interpreted.*